Therapeutic Apixaban (Eliquis) Dosing
The therapeutic dose of apixaban depends on the indication: for atrial fibrillation, use 5 mg twice daily (or 2.5 mg twice daily if ≥2 dose-reduction criteria are met); for acute DVT/PE treatment, use 10 mg twice daily for 7 days then 5 mg twice daily; for extended VTE prevention after initial treatment, use 2.5 mg twice daily. 1
Dosing by Indication
Atrial Fibrillation (Stroke Prevention)
Standard dose: 5 mg orally twice daily 1
Reduced dose: 2.5 mg orally twice daily if the patient has at least 2 of the following criteria 1, 2:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical pitfall: Do NOT reduce the dose if only 1 criterion is present. Research demonstrates that patients with a single dose-reduction criterion who received 5 mg twice daily had similar efficacy and safety compared to those without any criteria 3. Inappropriately reducing the dose in patients with only 1 criterion leads to suboptimal anticoagulation and increased thrombotic risk 4.
The 2024 ACC/AHA/ACCP/HRS guidelines confirm these dosing recommendations across the spectrum of renal function, with 5 mg or 2.5 mg twice daily appropriate even in patients with CrCl 15-30 mL/min 2.
Acute DVT/PE Treatment
Initial 7 days: 10 mg orally twice daily
After 7 days: 5 mg orally twice daily 1
This is the full therapeutic regimen for acute venous thromboembolism treatment.
Extended VTE Prevention (After ≥6 Months of Treatment)
Reduced dose: 2.5 mg orally twice daily 1, 5
The 2021 CHEST guidelines suggest using reduced-dose apixaban (2.5 mg twice daily) over full-dose (5 mg twice daily) for extended-phase anticoagulation after completing initial VTE treatment 5. This recommendation is supported by the AMPLIFY-EXT trial, which demonstrated that 2.5 mg twice daily reduced recurrent VTE from 8.8% to 1.7% compared to placebo, with minimal increase in bleeding (major bleeding 0.2% vs 0.5% with placebo) 6.
Recent evidence (2025): For provoked VTE with enduring risk factors, apixaban 2.5 mg twice daily for 12 months reduced recurrent VTE from 10.0% to 1.3% compared to placebo, with only 1 major bleed in the apixaban group 7. In cancer-associated VTE, dose reduction to 2.5 mg twice daily after 6 months of full-dose treatment decreased bleeding without loss of efficacy 8.
Post-Surgical VTE Prophylaxis
Hip or knee replacement: 2.5 mg orally twice daily
- Start 12-24 hours after surgery
- Duration: 35 days (hip replacement) or 12 days (knee replacement) 1
Dose Adjustments for Drug Interactions
When apixaban is coadministered with combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir):
- If taking 5 mg or 10 mg twice daily: reduce dose by 50%
- If already taking 2.5 mg twice daily: avoid coadministration 1
Key Clinical Considerations
Renal function: Unlike some other DOACs, apixaban dosing for atrial fibrillation remains 5 mg or 2.5 mg twice daily even with CrCl as low as 15 mL/min, though only 27% of clearance is renal 2, 9. The dose-reduction criteria for AF are based on age, weight, and creatinine level—not calculated creatinine clearance.
Missed dose: Take as soon as possible on the same day; resume twice-daily dosing. Never double the dose 1.
Perioperative management: Discontinue 48 hours before high-bleeding-risk procedures or 24 hours before low-bleeding-risk procedures (when CrCl >25 mL/min) 2, 1.